By leveraging digital endpoints, clinical trials can be more patient-centric, data-driven, and adaptable to meet the evolving needs of healthcare research. Further, FDA recently qualified the first digital endpoint for clinical trials, which will revolutionize how outcomes are measured, enhancing accuracy and efficiency in research.
And while digital endpoints’ potential is undeniable, widespread adoption remains a challenge. Decision-makers lack clear value assessments, routine use cases, and efficient deployment strategies around digital endpoints, hindering their numerous benefits.
To address this, DATAcc by DiMe is developing a framework and resources to help you build a compelling case for continued investment in digital strategies aligning with business goals and industry standards.
Sign up to receive updates on this important work
Findings from DiMe’s partnership with the Tufts Center for the Study of Drug Development and industry leaders at Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed showcase evidence of significant cost reductions and financial benefits tied to leveraging digital endpoints in trials.
We must continue to advance the use of digital endpoints to enhance clinical trials, leading to improved healthcare delivery.
To benchmark the field’s progress, DATAcc by DiMe’s Library of Digital Endpoints highlights industry-sponsored studies of new medical products or applications to advance the use of digital endpoints to speed medical product development.
